W
#Novartis #Pharmaceuticals #Oncology
www.wsj.com
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
Novartis is paying $2 billion upfront and up to $1 billion subject to targets to acquire Pikavation Therapeutics. fabrice coffrini/Agence France-Presse/Getty Images
Novartis NOVN -1.
#Novartis #oncology #breastcancer
www.morningstar.com
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion -- Update
Novartis struck a deal valued at up to $3 billion to buy an experimental breast-cancer drug from Synnovation Therapeutics, moving to bolster its oncology pipeline with a new treatment approach.
